WO2003092714A3 - Peptide variants of ige constrained by beta-lactam bond - Google Patents

Peptide variants of ige constrained by beta-lactam bond Download PDF

Info

Publication number
WO2003092714A3
WO2003092714A3 PCT/EP2003/004551 EP0304551W WO03092714A3 WO 2003092714 A3 WO2003092714 A3 WO 2003092714A3 EP 0304551 W EP0304551 W EP 0304551W WO 03092714 A3 WO03092714 A3 WO 03092714A3
Authority
WO
WIPO (PCT)
Prior art keywords
ige
constrained
beta
present
lactam bond
Prior art date
Application number
PCT/EP2003/004551
Other languages
French (fr)
Other versions
WO2003092714A2 (en
Inventor
Y De Bassols Carlota Vinals
Ralph Biemans
Lena Susanna Chomez
Original Assignee
Glaxosmithkline Biolog Sa
Y De Bassols Carlota Vinals
Ralph Biemans
Lena Susanna Chomez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Y De Bassols Carlota Vinals, Ralph Biemans, Lena Susanna Chomez filed Critical Glaxosmithkline Biolog Sa
Priority to AU2003229761A priority Critical patent/AU2003229761A1/en
Publication of WO2003092714A2 publication Critical patent/WO2003092714A2/en
Publication of WO2003092714A3 publication Critical patent/WO2003092714A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel medicaments are epitopes or mimotopes derived from IgE which are structurally constrained by a β-lactam bond. The novel regions presented may be the target for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to methods for production of the medicaments, pharmaceutical compositions containing them and their use in medicine. Also forming an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding the IgE regions of the present invention, and their use in medicine as passive immunotherapy or immunoprophylaxis.
PCT/EP2003/004551 2002-04-30 2003-04-28 Peptide variants of ige constrained by beta-lactam bond WO2003092714A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003229761A AU2003229761A1 (en) 2002-04-30 2003-04-28 Peptide variants of ige constrained by beta-lactam bond

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0209878.8A GB0209878D0 (en) 2002-04-30 2002-04-30 Vaccine
GB0209878.8 2002-04-30

Publications (2)

Publication Number Publication Date
WO2003092714A2 WO2003092714A2 (en) 2003-11-13
WO2003092714A3 true WO2003092714A3 (en) 2004-03-18

Family

ID=9935802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004551 WO2003092714A2 (en) 2002-04-30 2003-04-28 Peptide variants of ige constrained by beta-lactam bond

Country Status (3)

Country Link
AU (1) AU2003229761A1 (en)
GB (1) GB0209878D0 (en)
WO (1) WO2003092714A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102702359A (en) * 2004-02-02 2012-10-03 泰勒公司 Identification of novel igE epitopes
KR101413844B1 (en) 2008-12-09 2014-06-30 화이자 백신스 엘엘씨 IgE CH3 PEPTIDE VACCINE
EP2459214A1 (en) 2009-07-30 2012-06-06 Pfizer Vaccines LLC Antigenic tau peptides and uses thereof
HUE037416T2 (en) 2009-09-03 2018-08-28 Pfizer Vaccines Llc Pcsk9 vaccine
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269455A2 (en) * 1986-11-28 1988-06-01 Takeda Chemical Industries, Ltd. Highly purified fused protein comprising human IgE Fc fragment and production thereof
WO2000050461A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
WO2000050460A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
WO2002016409A2 (en) * 2000-08-22 2002-02-28 Glaxosmithkline Biologicals S.A. Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies
WO2002034288A2 (en) * 2000-10-27 2002-05-02 Smithkline Beecham Biologicals S.A. Vaccine for treating allergy
EP1262491A2 (en) * 2001-05-22 2002-12-04 Pfizer Products Inc. Non-anaphylactogenic IgE vaccines
US6500660B1 (en) * 1996-11-27 2002-12-31 Université Catholique de Louvain Chimeric target molecules having a regulatable activity

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269455A2 (en) * 1986-11-28 1988-06-01 Takeda Chemical Industries, Ltd. Highly purified fused protein comprising human IgE Fc fragment and production thereof
US6500660B1 (en) * 1996-11-27 2002-12-31 Université Catholique de Louvain Chimeric target molecules having a regulatable activity
WO2000050461A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
WO2000050460A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
WO2002016409A2 (en) * 2000-08-22 2002-02-28 Glaxosmithkline Biologicals S.A. Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies
WO2002034288A2 (en) * 2000-10-27 2002-05-02 Smithkline Beecham Biologicals S.A. Vaccine for treating allergy
EP1262491A2 (en) * 2001-05-22 2002-12-04 Pfizer Products Inc. Non-anaphylactogenic IgE vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ASERO RICCARDO ET AL: "Sera from patients with multiple drug allergy syndrome contain circulating histamine-releasing factors.", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY. SWITZERLAND JUL 2003, vol. 131, no. 3, July 2003 (2003-07-01), pages 195 - 200, XP002264568, ISSN: 1018-2438 *
LEGENDRE D ET AL: "Engineering a regulatable enzyme for homogeneous immunoassays.", NATURE BIOTECHNOLOGY. UNITED STATES JAN 1999, vol. 17, no. 1, January 1999 (1999-01-01), pages 67 - 72, XP002264567, ISSN: 1087-0156 *

Also Published As

Publication number Publication date
AU2003229761A1 (en) 2003-11-17
AU2003229761A8 (en) 2003-11-17
GB0209878D0 (en) 2002-06-05
WO2003092714A2 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
MXPA01008612A (en) Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses.
UA90457C2 (en) Human monoclonal antibody that specifically binds to human m-csf
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004018649A3 (en) Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
WO2006021955A3 (en) Use of bat monoclonal antibody for immunotherapy
WO2002043661A3 (en) Recombinant anti-cd30 antibodies and uses thereof
WO2003092624A3 (en) Use of heat shock proteins to enhance efficacy of antibody therapeutics
WO2007044756A3 (en) Monoclonal antibodies recognizing human ccr8
WO2004103306A3 (en) Immunosuppressant compounds and compositions
WO2004113330A8 (en) Immunosuppressant compounds and compositions
WO2007033230A3 (en) Anti-cd3 antibody formulations
WO2001001748A3 (en) Peptide compounds that bind her2
WO2005120558A3 (en) Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
WO2005080428A3 (en) Anti-epcam immunoglobulins
WO2004094473A3 (en) Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
WO2003075846A3 (en) Uses of monoclonal antibody 8h9
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
WO2003092714A3 (en) Peptide variants of ige constrained by beta-lactam bond
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
MXPA01008613A (en) Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses.
WO2002034288A8 (en) Vaccine for treating allergy
WO2004083382A3 (en) Compositions and methods for treating hyperimmune response in the eye
WO2007044574A3 (en) Pharmaceutical compositions, methods of preparation thereof, and methods of treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP